3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Melanoma
19
Thyroid Neoplasms
7
Glioma
6
Thyroid Carcinoma, Anaplastic
5
Multiple Myeloma
5
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
4
Neoplasm Metastasis
4
Colorectal Neoplasms
4
Thyroid Cancer, Papillary
3
Hematologic Neoplasms
3
Skin Neoplasms
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Histiocytosis, Langerhans-Cell
2
Glioblastoma
2
Colonic Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Adenocarcinoma, Follicular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Sarcoma
1
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
dabrafenib
×
1 year
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled